Advisornet Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Advisornet Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13	Closed	-$166	–	2124
2024 Q3	$166	Hold	13	–	–	﹤0.01%	2135
2024 Q2	$174	Hold	13	–	–	﹤0.01%	2045
2024 Q1	$302	Sell	13 -34	-72%	-$596	﹤0.01%	1930
2023 Q4	$606	Hold	47	–	–	﹤0.01%	2039
2023 Q3	$938	Hold	47	–	–	﹤0.01%	1809
2023 Q2	$1.25K	Hold	47	–	–	﹤0.01%	1827
2023 Q1	$2.72K	Hold	47	–	–	﹤0.01%	1622
2022 Q4	$2.38K	Hold	47	–	–	﹤0.01%	1633
2022 Q3	$4K	Hold	47	–	–	﹤0.01%	1556
2022 Q2	$3K	Hold	47	–	–	﹤0.01%	1623
2022 Q1	$5K	Hold	47	–	–	﹤0.01%	1618
2021 Q4	$5K	Sell	47 -6	-11%	-$598	﹤0.01%	1654
2021 Q3	$5K	Hold	53	–	–	﹤0.01%	1619
2021 Q2	$8K	Hold	53	–	–	﹤0.01%	1469
2021 Q1	$8K	Buy	53 +13	+33%	+$2.74K	﹤0.01%	1420
2020 Q4	$9K	Hold	40	–	–	﹤0.01%	1315
2020 Q3	$9K	Hold	40	–	–	﹤0.01%	1300
2020 Q2	$11K	Buy	40 +7	+21%	+$2.07K	﹤0.01%	1284
2020 Q1	$10K	Buy	+33	New	+$9.1K	﹤0.01%	1265

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Advisornet Financial's KPTI Position: Q4 2024 in Review

Advisornet Financial sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 13 shares — an estimated $166 sold.

Advisornet Financial first reported a position in KPTI in Q1 2020 and held it in 19 quarters. The position peaked at $11K in Q2 2020. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

Advisornet Financial reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
Advisornet Financial sold 13 Karyopharm Therapeutics shares in Q4 2024, an estimated $166.
Advisornet Financial first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 19 quarters.
Advisornet Financial's Karyopharm Therapeutics position peaked at $11K in Q2 2020.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Advisornet Financial's 13F filing for Q4 2024, filed 13 Jan 2025.